| p53 regulates hematopoietic stem cell quiescence Y Liu, SE Elf, Y Miyata, G Sashida, Y Liu, G Huang, S Di Giandomenico, ... Cell stem cell 4 (1), 37-48, 2009 | 649 | 2009 |
| Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways T Tauchi, K Shin-Ya, G Sashida, M Sumi, A Nakajima, T Shimamoto, ... Oncogene 22 (34), 5338-5347, 2003 | 257 | 2003 |
| Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders T Muto, G Sashida, M Oshima, GR Wendt, M Mochizuki-Kashio, Y Nagata, ... Journal of Experimental Medicine 210 (12), 2627-2639, 2013 | 216 | 2013 |
| Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia S Tanaka, S Miyagi, G Sashida, T Chiba, J Yuan, M Mochizuki-Kashio, ... Blood, The Journal of the American Society of Hematology 120 (5), 1107-1117, 2012 | 214 | 2012 |
| Telomeres and telomerase in hematologic neoplasia JH Ohyashiki, G Sashida, T Tauchi, K Ohyashiki Oncogene 21 (4), 680-687, 2002 | 214 | 2002 |
| Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation G Sashida, H Harada, H Matsui, M Oshima, M Yui, Y Harada, S Tanaka, ... Nature communications 5 (1), 4177, 2014 | 194 | 2014 |
| Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner M Mochizuki-Kashio, K Aoyama, G Sashida, M Oshima, T Tomioka, ... Blood, The Journal of the American Society of Hematology 126 (10), 1172-1183, 2015 | 138 | 2015 |
| The loss of Ezh2 drives the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition G Sashida, C Wang, T Tomioka, M Oshima, K Aoyama, A Kanai, ... Journal of Experimental Medicine 213 (8), 1459-1477, 2016 | 109 | 2016 |
| Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination T Yasuda, M Koiwa, A Yonemura, K Miyake, R Kariya, S Kubota, ... Cell reports 34 (8), 2021 | 104 | 2021 |
| Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator T Kameda, K Shide, T Yamaji, A Kamiunten, M Sekine, Y Taniguchi, ... Blood, The Journal of the American Society of Hematology 125 (2), 304-315, 2015 | 96 | 2015 |
| The ability of MLL to bind RUNX1 and methylate H3K4 at PU. 1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations G Huang, X Zhao, L Wang, S Elf, H Xu, X Zhao, G Sashida, Y Zhang, Y Liu, ... Blood, The Journal of the American Society of Hematology 118 (25), 6544-6552, 2011 | 89 | 2011 |
| The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior Y Liu, SE Elf, T Asai, Y Miyata, Y Liu, G Sashida, G Huang, ... Cell cycle 8 (19), 3120-3124, 2009 | 85 | 2009 |
| Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells M Misawa, T Tauchi, G Sashida, A Nakajima, K Abe, JH Ohyashiki, ... International journal of oncology 21 (5), 1087-1092, 2002 | 83 | 2002 |
| Akt Phosphorylates the Transcriptional Repressor Bmi1 to Block Its Effects on the Tumor-Suppressing Ink4a-Arf Locus Y Liu, F Liu, H Yu, X Zhao, G Sashida, A Deblasio, M Harr, QB She, ... Science signaling 5 (247), ra77-ra77, 2012 | 72 | 2012 |
| Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells T Tauchi, A Nakajima, G Sashida, T Shimamoto, JH Ohyashiki, K Abe, ... Clinical cancer research 8 (11), 3341-3347, 2002 | 71 | 2002 |
| BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells T Tauchi, M Sumi, A Nakajima, G Sashida, T Shimamoto, K Ohyashiki Clinical cancer research 9 (11), 4267-4273, 2003 | 60 | 2003 |
| Epigenetic regulation of hematopoiesis G Sashida, A Iwama International journal of hematology 96, 405-412, 2012 | 58 | 2012 |
| Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm S Kubota, K Tokunaga, T Umezu, T Yokomizo-Nakano, Y Sun, M Oshima, ... Nature communications 10 (1), 1653, 2019 | 54 | 2019 |
| Pathobiological pseudohypoxia as a putative mechanism underlying myelodysplastic syndromes Y Hayashi, Y Zhang, A Yokota, X Yan, J Liu, K Choi, B Li, G Sashida, ... Cancer discovery 8 (11), 1438-1457, 2018 | 53 | 2018 |
| Cyclin C regulates human hematopoietic stem/progenitor cell quiescence Y Miyata, Y Liu, V Jankovic, G Sashida, JM Lee, JH Shieh, T Naoe, ... Stem cells 28 (2), 308-317, 2010 | 53 | 2010 |
Motomi OsatoCancer Science Institute, National University of Singapore確認したメール アドレス: nus.edu.sg
